[讨论]GWD-8-Q5

hhdty

我看大家都没有问这个问题

Frazier and Mosteller assert that

medical research could be improved by

a move toward larger, simpler clinical

Line      trials of medical treatments. Currently,

(5)        researchers collect far more background

information on patients than is strictly

required for their trials—substantially more

than hospitals collect—thereby escalating

costs of data collection, storage, and

(10)      analysis. Although limiting information

collection could increase the risk that

researchers will overlook facts relevant

to a study, Frazier and Mosteller contend

that such risk, never entirely eliminable

(15)      from research, would still be small in most

studies. Only in research on entirely new

treatments are new and unexpected variables

likely to arise.

Frazier and Mosteller propose not

(20)      only that researchers limit data collection

on individual patients but also that

researchers enroll more patients in clinical

trials, thereby obtaining a more representative

sample of the total population with

(25)      the disease under study. Often researchers

restrict study participation to patients

who have no ailments besides those being

studied. A treatment judged successful

under these ideal conditions can then

(30)      be evaluated under normal conditions.

Broadening the range of trial participants,

Frazier and Mosteller suggest, would

enable researchers to evaluate a treatment’s

efficacy for diverse patients under

(35)      various conditions and to evaluate its

effectiveness for different patient subgroups.

For example, the value of a

treatment for a progressive disease may

vary according to a patient’s stage of

(40)      disease. Patients’ ages may also affect

a treatment’s efficacy.

GWD-8-Q5 :

The author mentions patients’ ages(line 40) primarily in order to

1. identify the most critical variable differentiating subgroups of patients

2. cast doubt on the advisability of implementing Frazier and Mosteller’s proposals about medical research

3. indicate why progressive diseases may require different treatments at different stages

4. illustrate a point about the value of enrolling a wide range of patients in clinical trials

5. substantiate an argument about the problems inherent in enrolling large numbers of patients in clinical trials

--------------------------------------------------------------------------------

answer: D

我现在也认同D是没有问题得,但是为什么C不对那,难道C只是例子里面得一个小的方面,而D中说的范围更大?

谢谢

hhdty

试验一下可否贴图

[此贴子已经被作者于2007-4-23 23:42:11编辑过]